Sonova shares rose to a 16-month high on October 8 after Goldman Sachs upgraded the Swiss hearing-aid maker from Neutral to Buy and raised its target price from 230 Swiss francs to 315 Swiss francs. According to Sina Finance, Goldman Sachs said new product launches, market share gains in Asia, and improving industry fundamentals could help Sonova's revenue and profit growth exceed market expectations.

Goldman Sachs said Sonova may grow faster than the overall global hearing-aid industry in the coming years, supported by the Virto R product, expansion in U.S. retail channels, and growth in Asia-Pacific business. The bank also said Sonova's Japan revenue in the last six months of fiscal 2026 rose 30% to 45% year on year at constant exchange rates.

For fiscal 2027, Goldman Sachs expects Sonova's first-half revenue to rise about 9% at constant exchange rates, above the Visible Alpha consensus estimate of 6.2%. It also expects full-year revenue growth of 7.8%, compared with a market consensus of 6.6%, and adjusted EBIT growth of 12.6%.

Goldman Sachs raised its revenue forecasts for fiscal 2027 to fiscal 2029 by 4% to 7%, and lifted its adjusted EBIT and earnings per share forecasts for the same period by 7% to 10%. The bank said Sonova's fiscal 2027 first-half results, due on November 12, will be a key catalyst.